1 according to a method described previously. 2 When the results were compared with those for the E. coli JM/109 transformant, Tf1 (Table I) , they were found to agree. V max of the TEM-8 ESBL for ceftazidime (relative to that of benzylpenicillin, which was taken as 100) is therefore 1460 94 (95% confidence interval), rather than 261, the value published earlier; the values for the other kinetic parameters (Table I) were in accord with those reported previously. We then checked the purities of the substrates used in the present study by H-400 MHz NMR and found them (in particular, ceftazidime) to be 95% pure. Unfortunately, none of the ceftazidime used in the original investigation 1 was available. However, we suspect that the purity of this compound may have been low and that this was the explanation for the erroneous results reported initially.
The original TEM-8-producing isolate and its transconjugant, CF704, exhibited a greater degree of resistance to ceftazidime than to cefotaxime; the enzyme was therefore designated CAZ-2. The isolate and the transformant, Tf1, which have been studied here exhibited the same resistance phenotype (MICs of cefotaxime and ceftazidime, 64 mg/L and 256 mg/L, respectively). Thus, the results for V max are now consistent with the observed MICs.
In Table II , the main classification of extendedspectrum, TEM-type -lactamases, based on amino acid substitutions, is related to both the resistance phenotype (determined from the MICs) and to the Payne categorization scheme. 3 When the different amino acid substitutions are examined, it is possible to correlate them with various levels of -lactam resistance, thereby explaining some of the original names of the ESBLs, e.g. CAZ-1 indicating a greater resistance to ceftazidime than to cefotaxime and CTX-1 indicating the reverse. Accordingly, a single mutation at position 164 [serine (Ser) in place of arginine (Arg)] (numbered according to Ambler et al. 4 ) leads to a significant level of resistance to ceftazidime (CAZa phenotype), as is the case with TEM-7 and TEM-12. High-level resistance to ceftazidime, cefotaxime and aztreonam (CAZb phenotype) also correlates with an amino acid substitution at position 164 (Ser in place of Arg), but with additional substitutions at positions 104 and/or 237 and/or 240. When the substitution is at position 238 [Ser in place of glycine (Gly)], the resistance phenotype is usually CTX, as for TEM-3.
The TEM-8 -lactamase was classified in Payne group 3, which embraces the ESBLs that preferentially hydrolyse cefotaxime. However, according to our results, the TEM-8 -lactamase should be reassigned to group 2 because of its high activity against ceftazidime. Furthermore, TEM-8 has a serine residue at position 238 and a ceftazidimase phenotype, an association not previously recognized. This paradox is presumably attributable to the presence of serine residues at both positions 164 and 238, a combination that is unique among TEM-type ESBLs. We therefore propose the phenotype CAZc for the TEM-8 -lactamase. Table I . Kinetic parameters of the -lactamases of the CF704 reference strain and the transformant, Tf1 Benzylpenicillin  100  6  100  9  Ceftazidime  1460 94  145  1404 135  135  Cefotaxime  640 14  75  667 16  72  Aztreonam  210 12  62  195 7  65 a Relative to benzylpenicillin, which was taken as 100. Sir, The antimicrobial properties of some plant-derived essential oils have been recognized for centuries, 1 but confirmed only recently. 2, 3 These activities are thought to be related to certain components of the oils, with citral, geraniol, eugenol, menthol and cinnamic aldehyde being particularly active. 4 Interest in the oils has increased following suggestions that they might be of use in the eradication of methicillin-resistant Staphylococcus aureus (MRSA) carriage 3, 5 which, until now, has relied on topical agents such as mupirocin. Other topical preparations, including chlorhexidine, have a role in eliminating or reducing colonization with vancomycin-resistant enterococci (VRE). 6 However, the development of resistance to these agents will limit their efficacies in the future and there is an urgent need therefore to identify alternatives. The present study was undertaken to assess the in-vitro activities of five essential oils which have been reported as having antibacterial properties. 1, 5 The oils studied included Melaleuca alternifolia (tea tree), Thymus vulgaris (thyme), Juniperus communis (juniper), Mentha piperita (peppermint) and Lavandula angustifolia (lavender), all of which were obtained from Napier, Edinburgh, UK; the sterility of the oils was checked by making 1 in 1000 dilutions in broth, incubating the dilutions in air for 5 days at 37°C and assessing growth. The test organisms, which were isolated from in-patients of the West Glasgow Hospitals Trust, included 15 nonreplicate strains of MRSA and five of VRE. All of the VRE isolates were identified as Enterococcus faecium. S. aureus NCTC 6571 was run in parallel as a control.
Susceptibility was determined by a broth microdilution method described previously by Carson et al. 3 The medium used was Brain Heart Infusion broth (Oxoid, Basingstoke, UK) supplemented with 0.5% Tween 80 (BDH, Poole, UK). Each oil was initially mixed with ethanol in a ratio of 1:3 in order to facilitate solubilization. Doubling dilutions were performed in 96-well microtitre plates (Nunc, Copenhagen, Denmark) to give concentrations ranging from 2% to 0.12% (v/v). Overnight broth cultures of each isolate and the control were adjusted so that the suspensions initially contained 10 8 cfu/L. The MIC was defined as the lowest concentration of each oil that inhibited visible growth after overnight incubation in air at 37°C. The contents of the wells containing no visible growth were subcultured on to blood agar plates and the MBC was defined as the lowest concentration that reduced the original inoculum by 99.9% after overnight incubation in air at 37°C.
The bacteriostatic and bactericidal activities of the five essential oils against the 15 strains of MRSA and five of VRE are shown in the Table. Tea tree oil was the most potent of the five oils, with MIC 90 s and MBC 90 s for the MRSA strains of 0.25% and 0.5%, respectively; these results are identical to those reported previously for strains isolated in both the UK and Australia. 3 The activities of lavender, peppermint and thyme oils against the MRSA isolates were virtually the same, the MIC 90 s being one dilution lower than those of tea tree oil, while the MBC 90 s were the same as those of tea tree oil. Juniper oil was the 305 Depending on the oil, the VRE strains were up to four-fold less susceptible than the MRSA isolates to tea tree, lavender, mint and thyme oils, the activities of which were equivalent. The MICs and MBCs of juniper oil for the VRE strains were, in common with those for the MRSA strains, 2%, a surprising observation in view of the longstanding reputation of this agent as an antiseptic. 1 The good in-vitro activities of four of the five plant essential oils evaluated here against MRSA and VRE isolates suggest that these agents may have potential for topical use, and clinical trials designed to assess their efficacies in vivo are warranted. Commercial preparations of tea tree oil containing concentrations between five-and ten-fold greater than the MICs for MRSA isolates are already available and there is no apparent reason why similar preparations of other oils should not be forthcoming. Owing to their more pleasant odour and 'greener' image than current topical formulations, essential oils may have the added advantage of being more acceptable to patients. It is worth remembering, however, that the current practice of incorporating sub-inhibitory concentrations of oils of medical use in cosmetics may undermine the potential efficacies of these compounds. 1 recently reported the detection of an extended-spectrum -lactamase (ESBL) in a strain of Klebsiella pneumoniae by a double-disc diffusion test, the methodology of which had originally been described by Jarlier et al. 2 These investigators, in common with Bush, 3 expressed their concerns that, as the result of the production of ESBLs, pathogens which are resistant to broadspectrum -lactams, e.g. cefotaxime, ceftazidime and aztreonam, may appear to be susceptible when tested by routine susceptibility testing methods, thereby leading to treatment failures. To illustrate this point, Karas et al. 1 described the clinical failure of cephalosporin therapy in a patient with a septicaemic episode caused by a strain of K. pneumoniae which was found to be susceptible by disc diffusion and MIC tests, but which was subsequently shown to be an ESBL producer. Our experience of using the double-disc diffusion test with Mueller-Hinton agar and an inoculum of 10 9 cfu/L to detect ESBL production 2 in more than 40 strains of K. pneumoniae isolated in three different hospitals not only confirms the observation of Karas et al. 1 but also suggests that, when the discs are appropriately arranged on a plate, the test can be used to 'fingerprint' K. pneumoniae isolates, as well as those of other species, such as Stenotrophomonas (Xanthomonas) maltophilia.
Differentiation of multiresistant Klebsiella pneumoniae isolates by a double-disc diffusion test for detecting extended-spectrumlactamases
Figures 1 and 2 demonstrate the susceptibility and ESBL patterns of K. pneumoniae strains isolated 6 months apart from two patients in a hospital in Ostrava, Czech Republic, and confirm that the two strains are different. Whilst strain 214 was of intermediate susceptibility to aztreonam and ofloxacin (Figure 1 ), strain 222 was resistant to aztreonam and highly susceptible to ofloxacin (Figure 2 ). Clavulanic acid inhibited the ESBL activity of strain 214, allowing an enhanced zone of inhibition around the aztreonam disc; a similar but less marked effect was observed with cefotaxime. With regard to strain 222, on the other hand, clavulanic acid inhibited ESBL activity against cefotaxime, ceftazidime and aztreonam. The plasmids conferring these phenotypes were transferable to Escherichia coli K-12 and Proteus mirabilis P-38 recipients (data not shown).
According to Bush, 4 aztreonam is not hydrolysed by the metallo--lactamases of S. maltophilia. However, Figure 3 shows that the basis of resistance of S. maltophilia strain 187 to aztreonam is an ESBL; similar observations were made in respect of some of the other 55 strains of S. maltophilia tested by us (data not shown).
Bush 3 recently questioned whether or not it is important to identify ESBL production in clinical isolates. On the basis of our experience and that of others, we suggest that it is. Sir, Clinafloxacin (CI-960; PD 127391) and PD 131628 (CI-990/PD 131112 being the therapeutic form) are among the most potent and broad-spectrum of the newer fluoroquinolones. However, there have been only a few reports 1,2 describing the in-vitro activities of these agents against Mycoplasma and Ureaplasma spp., principally because of the fastidious nature of these organisms, the corresponding technical demands associated with determining their in-vitro susceptibilities and the lack of a standardized methodology. We report here the MICs of these novel fluoroquinolones, compared with those of ciprofloxacin, clindamycin, erythromycin and tetracycline, for strains of Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum.
The Mycoplasmataceae tested included strains obtained from the American Type Culture Collection (Rockville, MD, USA) and clinical isolates from southeastern Michigan; all strains were plated on to mycoplasma agar plates in order to confirm that the cultures were pure. The susceptibility test media and the methodology were modifications of those described by Waites et al.; 2 the temperature of incubation at all times was 35°C in an ambient atmosphere. H broth, 3 which was developed for growing M. hominis, was modified to contain 14.7 g of PPLO broth (Difco Laboratories, Detroit, MI, USA), 0.02 g of phenol red (Sigma Chemical Co., St Louis, MO, USA) and 10 g of arginine (Sigma), all of which were suspended in 700 mL of water. The suspension was autoclaved, supplemented with 100 mL of 25% yeast extract (BBL Microbiology Systems, Cockeysville, MD, USA) and 200 mL of filtered horse serum (Colorado Serum Co., Denver, CO, USA) and the pH adjusted to 7.0; the medium was stored for no more than 2 weeks at 4°C. M. pneumoniae SP-4 medium, comprising 3.5 g of mycoplasma broth base without crystal violet (BBL), 10 g of Bacto-tryptone (Difco), 5.3 g of Bacto-peptone (Difco) and 5 g of Bacto-glucose (Difco), was suspended in 591 mL of water and autoclaved. To this were added 50 mL of CMRL 1066 medium (Gibco BRL, Gaithersburg, MD, USA), 35 mL of fresh yeast extract (Gibco), 100 mL of 2% yeastolate (Difco), 170 mL of freshly thawed fetal bovine serum (triple filtered through a 0.1 m filter and heated at 56°C for 1 h) (Hyclone Laboratories Inc., Logan, UT, USA) and 20 mL of 0.1% phenol red as described previously, 4 as well as 34 mL of fresh 200 mM L-glutamine (Gibco); the pH of the suspension was finally adjusted to 7.5. U. urealyticum urea 10B medium 2 was modified to contain 14 g of mycoplasma broth base without crystal violet (BBL), 25 g of yeast extract, 0.2 g of DNA from herring testes (Sigma), 1 mL of 1% phenol red and 10 mL of 2 N HCl, all of which were suspended in 777.5 mL of water. After the suspension had been autoclaved, 200 mL of prefiltered horse serum (Hyclone), 5 mL of IsoVitaleX (BBL), 4 mL of 10% urea (J. T. Baker Inc., Phillipsburg, NJ, USA) and 2.5 mL of 4% L-cysteine (Sigma) were added and the pH adjusted to 5.9-6.0. Reliable growth was achieved with media components obtained from the indicated sources and prepared freshly.
MICs were determined by a broth microdilution method. Each strain was suspended in 5 mL of broth which was diluted in ten-fold increments; all of the tubes were then incubated until a change in the colour indicator was observed (usually after 2-10 days). The contents of the tubes containing the highest dilutions displaying colour changes were recultured in fresh medium and the resulting suspensions frozen and maintained as stock cultures. The inocula for the MIC determinations were calculated in terms of colour change units (ccu). An aliquot of each stock culture was thawed in an incubator for 1 h and diluted in ten-fold increments. The 200 L dilutions in microtitre trays were then incubated; U. urealyticum cultures were covered with sealer tape (Corning Costar Corp., Cambridge, MA, USA). The colour change endpoint following incubation of M. hominis and U. urealyticum for 72 h and M. pneumoniae for 10 days represented 1 ccu.
At the time of testing, the stock cultures were thawed, placed in microtitre trays, diluted to give suspensions initially containing 10 7 -10 8 ccu/L and incubated for 1 h. Aliquots of 100 L were then added to equal volumes of two-fold dilutions of the various antibiotics. The MIC was defined as the lowest antibiotic concentration that allowed no colour change following incubation of U. urealyticum for 24-30 h, M. hominis for 48 h and M. pneumoniae for 4-7 days. The tests were performed in duplicate and validated, as described previously, 2 with the following controls: inoculated drug-free medium, uninoculated drug-free medium, uninoculated medium containing antibiotics at concentrations of 128 mg/L, and Staphylococcus aureus ATCC 29213.
Of the quinolones tested (Table), the results agreed closely, with the MICs of each quinolone for the individual species tested varying by no more than four-fold; similarly, the activities of the comparator drugs, clindamycin, erythromycin and tetracycline, were consistent with those reported by previous investigators. 2 The MICs of clinafloxacin were equivalent to or lower than those of the comparator agents and comparable to those reported recently for trovafloxacin and BAY 12-8039. 5, 6 The high in-vitro activities of novel fluoroquinolones against Mycoplasma and Ureaplasma spp. suggest that these antimicrobials might have potential in the treatment of respiratory and urogenital infections caused by these pathogens.
